Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
TB-500
Repair & Recovery
Molecular Dossier
- Rank Index: 7
- Status: FDA Category 1
- What does this mean?
- Molecular Structure: Synthetic Thymosin Beta-4 Fragment
About TB-500
TB-500 (Thymosin Beta-4 Fragment, LKKTETQ) is a 5-amino-acid synthetic peptide derived from the C-terminal region of the naturally occurring hormone thymosin beta-4, which plays a critical role in wound healing, tissue repair, and inflammation modulation. As of February 2026, TB-500 was reclassified from FDA Category 2 (restricted) to Category 1 status, enabling compounding pharmacy production under licensed physician prescription. Preclinical and early animal evidence shows TB-500 improves healing of surgical wounds, musculoskeletal injuries (tendons, ligaments, muscle), cardiac tissue repair post-infarction, and corneal wound healing. The proposed mechanism involves upregulation of VEGF-mediated neovascularization, collagen deposition, and anti-inflammatory macrophage polarization. As of May 2026, TB-500 has zero completed human randomized controlled trials (RCTs) — all available evidence is from animal models or observational case reports. Reclassification catalyzed the first formal Phase 2 human trials (wound healing, tendon repair) now enrolling. Parenteral administration (subcutaneous or intramuscular injection). Theoretical concerns regarding systemic immunomodulation (TB-500 is partially derived from immune tissue) remain unresolved in humans. Reclassification does NOT constitute FDA approval but permits clinical research and prescription-based compounding.
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which is found in high concentrations in blood platelets and wound fluid. Its primary function in biological systems is the regulation of actin, a vital protein for cell structure and movement. By sequestering G-actin, TB-500 facilitates rapid cell migration to sites of injury, making it a cornerstone compound in regenerative research.
Unlike other growth factors, TB-500 has a low molecular weight, allowing it to travel long distances through systemic circulation to locate and repair damaged tissue. Research suggests it promotes the differentiation of endothelial cells and the migration of keratinocytes, which are essential for skin and muscle repair. Its anti-inflammatory properties are further augmented by its ability to downregulate pro-inflammatory cytokines, reducing localized edema and accelerating recovery timelines.
Clinical Focus
Tissue Regeneration & Recovery
Archival Aliases
Repair Fragment, Thymosin Beta-4
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
What is the difference between Thymosin Beta-4 and TB-500?
TB-500 is a synthetic fraction (fragment 17-23) of the full-length Thymosin Beta-4 protein. This specific sequence is the active binding domain responsible for actin sequestration and cell migration. Research often favors TB-500 for its lower molecular weight and ease of tissue penetration compared to the full protein.
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 (Tβ4) is the full 43-amino acid naturally occurring protein. TB-500 is a synthetic fragment corresponding to amino acids 17-23 of Tβ4 (the actin-binding domain). TB-500 is believed to retain most of the healing and anti-inflammatory properties of the full molecule while being more practical to synthesize, making it the preferred research compound.
How does TB-500 promote tissue repair?
TB-500 works by sequestering G-actin monomers, which facilitates cell migration to injury sites. It promotes the differentiation of stem cells into tissue-specific cells, stimulates angiogenesis (new blood vessel formation), and downregulates pro-inflammatory cytokines including IL-6 and TNF-alpha. The result is accelerated healing across multiple tissue types: muscle, tendon, ligament, and skin.
What injuries respond best to TB-500?
Preclinical research shows particularly strong results for tendon and ligament injuries, muscle tears, and cardiovascular repair. TB-500 has been studied in equine models for tendon injuries (where it is legal for veterinary use) with documented improvements in healing speed and collagen fiber organization. Research also highlights benefits for chronic injuries where healing has stalled.
Does TB-500 have any cardiovascular benefits?
Yes. TB-500 has demonstrated cardioprotective effects in multiple animal models. Studies show it can stimulate cardiac progenitor cell migration to areas of damage, promote new vessel formation in ischemic tissue, and reduce cardiomyocyte apoptosis after infarction. A clinical trial (LTBR12) used a stabilized TB-500 formulation for cardiac repair following heart attack.
What protocol is commonly used in TB-500 research?
Common research protocols in animal studies involve a loading phase (higher doses weekly for 4-6 weeks) followed by a maintenance phase (lower doses bi-weekly for 4-8 weeks). Doses in human-applicable research contexts are often extrapolated from animal data. No human clinical trials have established optimal dosing, so research protocols remain theoretical.
Is TB-500 detectable in doping tests?
Yes. WADA (World Anti-Doping Agency) classifies Thymosin Beta-4 and its fragments as prohibited substances under the Peptide Hormones and Related Substances category. Detection methods including immunoassay and mass spectrometry can identify TB-500 metabolites in urine and blood. Detection windows vary based on dose and individual metabolism.
Can TB-500 be combined with BPC-157?
The BPC-157 + TB-500 combination (often called "The Wolverine Stack") is the most widely researched peptide combination for tissue repair. The two compounds work via complementary mechanisms: BPC-157 primarily promotes angiogenesis and tendon fibroblast growth factor signaling, while TB-500 facilitates cell migration and reduces systemic inflammation. Animal models suggest synergistic effects on recovery speed.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | Synthetic Thymosin Beta-4 Fragment |
| Primary Pathway | Repair & Recovery |
| Research Phase | FDA Category 1 |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-07